Abstract Although immunosuppressive treatments and target concentration intervention (TCI) have significantly contributed to the success of allogeneic haematopoietic cell transplantation (alloHCT), there is currently no consensus on the best immunosuppressive strategies. Compared with solid organ transplantation, alloHCT is unique because of the potential for bidirectional reactions (i.e. host-versusgraft and graft-versus-host). Postgraft immunosuppression typically includes a calcineurin inhibitor (cyclosporine or tacrolimus) and a short course of methotrexate after highdose myeloablative conditioning, or a calcineurin inhibitor and mycophenolate mofetil after reduced-intensity conditioning. There are evolving roles for the antithymyocyte globulins (ATGs) and sirolimus as postgraft immunosuppression. A review of the pharmacokinetics and TCI of the main postgraft immunosuppressants is presented in this two-part review. All immunosuppressants are characterized by large intra-and interindividual pharmacokinetic variability and by narrow therapeutic indices. It is essential to understand immunosuppressants' pharmacokinetic properties and how to use them for individualized treatment incorporating TCI to improve outcomes. TCI, which is mandatory for the calcineurin inhibitors and sirolimus, has become an integral part of postgraft immunosuppression. TCI is usually based on trough concentration monitoring, but other approaches include measurement of the area under the concentration-time curve (AUC) over the dosing interval or limited sampling schedules with maximum a posteriori Bayesian personalization approaches. Interpretation of pharmacodynamic results is hindered by the prevalence of studies enrolling only a small number of patients, variability in the allogeneic graft source and variability in postgraft immunosuppression. Given the curative potential of alloHCT, the pharmacodynamics of these immunosuppressants deserves to be explored in depth. Development of sophisticated systems pharmacology models and improved TCI tools are needed to accurately evaluate patients' exposure to drugs in general and to immunosuppressants in particular. Sequential studies, first without and then with TCI, should be conducted to validate the clinical benefit of TCI in homogenous populations; randomized trials are not feasible, because there are higherpriority research questions in alloHCT. In Part I of this article, we review the alloHCT process to facilitate optimal design of pharmacokinetic and pharmacodynamics studies. We also review the pharmacokinetics and TCI of calcineurin inhibitors and methotrexate.
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Introduction
Allogeneic haematopoietic cell transplantation (alloHCT) is a curative procedure used to treat various non-malignant and malignant blood disorders and metabolic disorders. The goal of alloHCT is to cure the patient-termed the 'host' or 'recipient'-of their underlying disease by replacing their haematopoietic cells with cells from a healthy donor. To achieve this cure, a delicate balance must be maintained between the immune system of the host and the donor stem cells (graft) that are infused into the host [1] . Transplantation of donor cells that are not genetically identical (i.e. allogeneic) can result in bidirectional immunological reactions [2] . This contrasts with solid organ transplantation, where the graft generally has a limited number of cells with immunological function and the main concern is preventing rejection of the donor organ by the recipient's immune system [1] . In alloHCT, grafting of cells from one individual to another provokes immunological reactions involved in engraftment of the donor cells, graft-versus-host disease (GVHD), control of a malignancy (termed 'graft versus tumour' [GVT]), and development of tolerance and immune reconstitution [2] . These immunological reactions are influenced by the conditioning regimen (also termed the 'preparative regimen'), the type and source of the donor graft and the postgraft immunosuppressive regimen (Fig. 1) , all of which are essential components of the alloHCT procedure. The substantive heterogeneity in the conditioning regimen, type of donor graft and postgraft immunosuppression, combined with variability in the recipient's characteristics, create challenges for completion of adequately powered pharmacokinetic/pharmacodynamic studies. The pharmacokinetics and pharmacodynamics of conditioning regimens have been reviewed elsewhere [3] [4] [5] [6] [7] . This review focuses upon the pharmacokinetics, pharmacodynamics and pharmacogenomics of postgraft immunosuppression in alloHCT recipients. The use of immunosuppressants to treat acute or chronic GVHD is not discussed.
For postgraft immunosuppression, the goal of pharmacokinetic/pharmacodynamic studies and personalized dosing through target concentration intervention (TCI) is to improve clinical outcomes by improving efficacy or decreasing toxicity. Improving outcomes can include preventing graft rejection, lowering the rates and/or severity of GVHD and avoiding excess immunosuppression. Excess immunosuppression should be avoided because of its association with more frequent and severe infectious complications, including bacterial, fungal and viral infections, which contribute to nonrelapse mortality (NRM). Focusing upon postgraft immunosuppression in alloHCT recipients, the goals of this review are to (1) provide the reader with an understanding of alloHCT to facilitate informative pharmacokinetic/pharmacodynamic studies; (2) review the available relevant pharmacokinetic data and population pharmacokinetic (popPK) models; and (3) review the available pharmacokinetic, pharmacodynamic and pharmacogenomic literature. The three main steps in the process of alloHCT are administration of (1) the conditioning regimen; (2) the donor cell infusion; and (3) postgraft immunosuppression ( Fig. 1) . Because alloHCT can treat various non-malignant and malignant diseases, there is substantive variability in the characteristics of the recipient prior to the alloHCT procedure. Most notable among these factors is recipient age, which can influence clinical outcomes and should be included in pharmacodynamic analyses. For example, thymus-dependent regeneration of CD4? and CD8? cells after chemotherapy occurs primarily in children [8, 9] , and engraftment kinetics after nonmyeloablative (i.e. low-dose) conditioning differ between children and adults [10] .
Conditioning Regimen
Administration of the conditioning regimen is the initial step of the alloHCT procedure. The conditioning regimen is administered before infusion of the donor cells, which occurs on transplant day 0 (Fig. 1) , and conditioning regimen days are shown by negative numbers (e.g. the conditioning regimen is administered on days -7 to -2). The initial rationale for myeloablative alloHCT was to circumvent dose-limiting myelosuppression with a stem cell infusion, thereby maximizing the potential value of the steep dose-response curve for alkylating agents and radiation [11] , suppressing the host immune system, and creating space in the marrow compartment to facilitate engraftment. The goal was to improve cancer cure rates with the increased chemotherapy doses. Unfortunately, myeloablative conditioning is associated with significant morbidity and NRM, wherein the alloHCT recipient dies while having no evidence of their underlying malignancy. This limits the use of myeloablative conditioning to younger patients or those with no or minimal pre-existing comorbidities. To expand the availability of this curative procedure to more patients, reduced-intensity conditioning (RIC) regimens have been developed over the past 15 years [12] . RIC regimens administer chemotherapy and/ or radiation therapy at lower doses than myeloablative regimens, with the intent of lowering NRM. Compared with myeloablative conditioning, RIC relies more on the GVT effect, via immune-mediated assistance from donor lymphocytes for complete eradication of malignant cells [13] . A subset of RIC regimens, nonmyeloablative regimens, administer the lowest conditioning doses of all and rely more heavily on the GVT effect provided by minor histocompatibility antigens (mHAs) on leukemic cells [2] . Notably, with RIC, the host's cells are still present at the time of donor graft infusion, leading to a chimeric state wherein the host and donor cells co-exist within the recipient. Therefore, postgraft immunosuppression must achieve a fine balance between the host and donor cells. Optimal donor chimerism varies by the cell type and intensity of the conditioning regimen [14] [15] [16] . Achieving the optimal donor T-cell chimerism levels early after alloHCT could lower rates of graft rejection and GVHD while maximizing the GVT effect [12] .
Infusion of Allograft
The infusion of the allogeneic donor stem cells occurs on transplant day 0 ( Fig. 1) , which is at least 24 h after administration of the last dose of the conditioning regimen. Stem cells, including haematopoietic cells, have the unique capacity to produce daughter cells that retain stem cell properties. Thus, these cells are self-renewing and provide a lifetime source of blood cells [2] . Allogeneic grafts initiate immune reactions related to histocompatibility; the severity of the reaction depends on the degree of incompatibility in the polymorphic class I and class II human leukocyte antigen (HLA) cell-surface glycoproteins [2] . Notably, recipients of cells from a genetically identical twin sibling, termed a 'syngeneic graft', do not receive postgraft immunosuppression; because the donor and the patient are genetically identical, GVHD should not be elicited. All other alloHCT recipients, however, are not genetically identical and must receive postgraft immunosuppression. The graft source influences the incidence of the pharmacodynamic end points (Table 1) [17] [18] [19] [20] . The ideal donor is a genotypically HLA-matched sibling, as these donors carry the lowest risk of GVHD. A substantive challenge in alloHCT, however, is finding a suitable donor: up to a third of Caucasian patients in need of alloHCT are unable to find such a donor [21] . Patients from racial or ethnic minorities face even greater difficulties in finding an appropriate donor [21] . There are three alternative graft sources for patients who need an alloHCT but do not have an HLA-matched sibling donor: an unrelated donor, umbilical cord blood (UCB) or an HLA-mismatched haploidentical donor [18, 19, 22] . These alternative graft sources, however, have additional risks or limitations. For example, grafts from HLA-matched unrelated donors are associated with more GVHD than is seen from HLA-matched related donors, although there is some controversy regarding these effects [23] .
Donor cells also vary by the anatomical site of cell collection. Specifically, cells may be collected from bone marrow, peripheral blood stem cells (PBSCs) or UCB. The collection site can influence clinical outcomes [20] and thus can affect pharmacokinetic/pharmacodynamic studies as well. In unrelated donor grafts, PBSCs may reduce the risk of rejection, whereas bone marrow may reduce the risk of chronic GVHD [24] . In addition, some donor grafts are manipulated, as in T-cell depletion (TCD), where a graft is rid of alloreactive T cells either ex vivo or in vitro [25] . Notably, recipients of TCD histocompatible grafts generally do not receive postgraft immunosuppression because the volume of donor T cells infused into the recipient is usually insufficient to elicit a significant graft-versus-host reaction [26, 27] .
When interpreting pharmacokinetic/pharmacodynamic studies of postgraft immunosuppression, attention must be paid to the HLA typing methods. There have been technological improvements in HLA typing, with great improvements in high-resolution allele typing for unrelated donor alloHCT [28, 29] . The impact of HLA allelic mismatches upon pharmacodynamic end points differs on the basis of the graft source [30, 31] . Beyond HLA matching, minor antigens encoded by genes on the Y chromosome account for a higher GHVD incidence and a lower relapse rate among male recipients of female donor grafts compared with male recipients of male donor grafts [2] .
Postgraft Immunosuppression
The third step of alloHCT is the administration of postgraft immunosuppression. The primary goal of postgraft immunosuppression is to ensure engraftment and prevent the development of GVHD while maintaining GVT. Immunosuppressants inhibit and minimize the activity of donor T cells. Immunosuppressive therapy is most often initiated either a few days prior to or just after completion of the infusion of donor stem cells on day 0.
The type of and compliance with the postgraft immunosuppression influence GVHD risk [1] . Postgraft immunosuppression varies between myeloablative and RIC regimens ( Table 2 ). Since myeloablative conditioning has been available for longer, there are more data from patients receiving myeloablative alloHCT than from those receiving RIC alloHCT. The initial regimens included singledrug therapy using cyclophosphamide, methotrexate or cyclosporine [32] [33] [34] . In most patient populations, randomized clinical trials after myeloablative conditioning have documented the superiority of combination postgraft immunosuppression compared with monotherapy with cyclophosphamide, methotrexate or cyclosporine [34] [35] [36] [37] .
A variety of two-and three-drug combination immunosuppressive regimens have been used for prophylaxis against GVHD. Cyclosporine or tacrolimus, [174] Graft source Low cell count Acute GVHD Degree of HLA mismatch between the recipient and donor [1] Degree of mismatching for non-HLA minor antigen disparities Graft source (e.g. UCB vs. haploidentical) [19] Relapse Kahl relapse risk
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Use of ATGs
ATGs antithymocyte globulins, C ss concentration at steady state, GVHD graft-versus-host disease, HLA human leukocyte antigen, TCD T-celldepleted, UCB umbilical cord blood methotrexate and mycophenolate mofetil (MMF) are the agents most commonly incorporated into combination immunosuppressive regimens. The most commonly used regimen-termed the 'Seattle regimen'-is a combination of methotrexate and a calcineurin inhibitor (CNI), either cyclosporine or tacrolimus [34, [38] [39] [40] [41] but there is no national consensus with regard to the most effective regimen. Several studies have compared three-drug and twodrug immunosuppression schemas. The incidence of acute GVHD is similar or lower with three-drug regimens, but infectious complications are higher and overall survival is similar to survival with two-drug regimens [42, 43] . After RIC regimens, postgraft immunosuppression varies more widely by transplant centre but most often consists of a combination of a CNI and MMF, a pairing that was also developed in Seattle [16, 44] . In alloHCT, postgraft immunosuppression may eventually be discontinued because the immunologically active tissues of the host and donor become tolerant of one another over time and no longer recognize each other as foreign. Therefore, in alloHCT recipients without GVHD, immunosuppressive therapy is slowly tapered and generally discontinued over 6 months [44] . This is in contrast to solid organ transplant recipients, where immunosuppressive therapy usually must be continued for the recipient's entire life.
3 Pharmacodynamic End Points
Rejection
Acceptance of the donor cells, termed 'engraftment', is critical to the success of alloHCT. Graft rejection after alloHCT can manifest as either a lack of initial engraftment or development of pancytopenia and marrow aplasia after initial engraftment [1] . Rejection, drug toxicity, sepsis and certain viral infections can all cause graft failure [1] . An absence of donor cells and the presence of recipient T cells are key findings to support the diagnosis of rejection in a patient with graft failure [1] . Because of the durable persistence of donor cells, however, rejection is unlikely, even when recipient T cells can be detected [1] . In patients receiving an RIC regimen, the risk of rejection can be influenced by donor chimerism. After administration of the RIC, the recipient's immune system is not completely ablated, such that both the donor and recipient cells are circulating within the patient. The development of quantitative chimerism monitoring, specifically evaluating the donor chimerism, provides a critical tool for patient prognosis and data on which to base clinical intervention in patients receiving RIC [45, 46] . The longitudinal changes in donor chimerism, termed 'engraftment kinetics', are influenced by several factors, including the type of alloHCT conditioning, the stem cell source and the intensity of postgraft immunosuppression [45, 47] . Donor chimerism is evaluated in different cell types (e.g. T cells, natural killer [NK] cells, granulocytes), and there is a trend for more frequent monitoring of chimerism after infusion of the donor graft [14, 45, [48] [49] [50] . Quantitative evaluation of chimerism most often uses a polymorphic system of DNA biomarkers, such as short tandem repeats (STRs) [46, [51] [52] [53] . STRs are short sequences of nucleotides that are variably and randomly repeated throughout the genome. Using this quantitative approach, it is possible to assess the full range of donor chimerism values, from 0 to 100 %.
Graft-Versus-Host Disease
GVHD is a leading cause of morbidity and mortality for alloHCT recipients [19] . Thus, its prevention is ideal. GVHD is initiated by donor T cells recognizing recipient major histocompatibility complex (MHC) class I alloantigens, class II alloantigens and minor mHAs on recipient antigen-presenting cells that persist after the pretransplant conditioning regimen [1] . Despite administration of postgraft immunosuppression, 60 % of alloHCT recipients develop acute GVHD in the first 100 days post-transplantation, and up to half develop chronic GVHD [25] . GVHD is categorized as acute or chronic on the basis of clinical manifestations. Acute GVHD is a clinical syndrome affecting primarily the skin, liver and gastrointestinal tract. Acute GVHD is staged by the number and extent of the organs affected and is classified into one of four grades (I-IV) depending on the degree or state of involvement of the affected sites [54] [55] [56] . In contrast, chronic GVHD can affect almost any organ system and closely resembles several autoimmune diseases. Immunemediated destruction of tissues, a hallmark of GVHD, disrupts the integrity of protective mucosal barriers and provides an environment that favours the establishment of opportunistic infections. The biological mechanisms leading to chronic GVHD are not as well understood as those leading to acute GVHD, and the relationship between acute and chronic GVHD is unclear [1] . Although acute GVHD is a risk factor for chronic GVHD, not all cases of acute GVHD evolve into chronic GVHD, and chronic GVHD can develop in the absence of any prior overt acute GVHD [1] . Chronic GVHD is the most frequent late complication of alloHCT, and it occurs in 30-70 % of long-term survivors of myeloablative alloHCT [57, 58] . In addition, chronic GVHD is the major cause of NRM and morbidity [59] [60] [61] .
Graft Versus Tumour
In alloHCT, donor lymphocytes can help eliminate malignant cells that survive the conditioning regimens. Without question, GVHD and GVT continue to be tightly linked in alloHCT recipients [13, 62, 63] . Our present understanding is that the donor T cells react with cells from the HLA-matched, genetically non-identical recipient. Donor T cells specifically target the host's nonhaematopoietic tissue, causing GVHD, and the haematological malignancy, causing a GVT response [64, 65] . Work is ongoing to segregate these polymorphic differences to allow donor T cells to react with host leukemic cells without damaging the non-haematopoietic tissues [65] .
Unique Considerations for Pharmacokinetic/ Pharmacodynamic Studies in AlloHCT
There are unique considerations for conducting pharmacokinetic/pharmacodynamic studies of immunosuppression in alloHCT recipients compared with those conducted for US Food and Drug Administration (FDA) approval of a new drug or in solid organ transplantation. The first consideration is the substantive variability in alloHCT clinical practice, both overall [66] and specifically in postgraft immunosuppression [67] . Most alloHCT recipients will eventually discontinue their immunosuppression and maintain a state of immune tolerance (see Sect. 2.3) [67] . There is, however, substantive variation in when immunosuppression is tapered, which agent is tapered first, how quickly these changes are made and the strategy underlying the planned immunosuppression taper [67] . This variation may influence the development of acute GVHD or chronic GVHD, which are often pharmacodynamic end points in pharmacokinetic/pharmacodynamic studies. Fortunately, efforts are underway to more rigorously study the effects of this variability in clinical practice [67] and to create international networks to develop worldwide priorities to address alloHCT issues [68] . The second consideration in conducting pharmacokinetic/pharmacodynamic studies of postgraft immunosuppression is the subjective assessment of both acute GVHD and chronic GVHD. Evaluating GVHD as a pharmacokinetic covariate is particularly challenging because assessing its severity involves subjective judgments in the interpretation of medical records and at the bedside [69] . The challenges present particular difficulties for multicentre or retrospective studies.
The role of covariates in the pharmacokinetics of immunosuppressed alloHCT recipients is a third consideration for pharmacokinetic/pharmacodynamic studies in these patients. Myeloablative conditioning regimens can be administered only to patients who are healthy enough to tolerate these regimens' considerable toxicity. Therefore, the myeloablative alloHCT population has minimal variability in renal or liver function, which may limit covariate analyses. In addition, the vast majority of alloHCT pharmacokinetic/pharmacodynamic studies are single-institution studies and often have small sample sizes, which can further limit covariate analyses and also the extent to which study results can be generalized.
The fourth consideration is the potential role of drugdrug interactions (DDIs) in alloHCT recipients [70] . In alloHCT, nearly all patients must contend with polypharmacy, and DDIs are often unpredictable and variable [71] . These DDIs exist between multiple immunosuppressants and supportive care medications, such as antifungal agents. Only recently has the magnitude of potential DDIs in postgraft immunosuppression in alloHCT recipients been published [72] . Much of what is currently known about potential DDIs is extrapolated from studies conducted in the setting of solid organ transplantation [73] [74] [75] . Examples of potential DDIs in alloHCT are those resulting from concomitant antibiotics or antifungals, which are needed because of the immunosuppression in alloHCT recipients [76] . The effect of antibiotics upon enterohepatic recirculation of MPA is difficult to study, because of inconsistent documentation regarding the precise initiation and discontinuation of antibiotics relative to the days of MPA pharmacokinetic sampling [77] . Furthermore, since MPA TCI has yet to be widely adopted, an antibiotic-MPA interaction is likely to be missed. Another example is the DDI between azole antifungals and CNIs, which can be managed through TCI [70] . The azoles have variable cytochrome P450 (CYP) 3A4 inhibition and potentially also affect CYP2C9, CYP2C19 and P-glycoprotein (Pgp). The risk of deleterious DDIs led to a change in the primary end point of prophylactic antifungal trials from invasive fungal infections to failure-free survival [78] . Failure-free survival provides a net assessment of the efficacy of the antifungal in preventing an invasive fungal infection and any negative effect of mortality from adverse events, some of which arise from deleterious DDIs [78] . Although these azole-immunosuppressive DDIs are well known, their management can be challenging and could benefit from improved pharmacokinetic/pharmacodynamic modelling.
Literature Search Methods
Extensive literature searches in PubMed were conducted using the immunosuppressants' generic names and the term 'allogeneic transplant*' (e.g. 'cyclosporine AND allogeneic transplant*' for cyclosporine manuscripts). Subsequent literature search terms were specified to the relevant topic-such as 'obesity AND cyclosporine AND allogeneic'. Additional references were added as needed on the basis of the authors' literature review. The tables in both Part I and Part II were predominantly constructed by JSM and MJB, with confirmation of data by JLB for Part II only.
Calcineurin Inhibitors
The CNIs, cyclosporine and tacrolimus, are an essential part of postgraft immunosuppression for alloHCT after myeloablative conditioning or RIC (Sect. 2.3). The CNIs are typically used in combination with methotrexate after myeloablative conditioning or with MMF after RIC ( Table 2 ). The section below describes both CNIs together because of their similar mechanisms of action and similar pharmacokinetic characteristics [79] . Clinically, however, there has been considerable discussion regarding whether cyclosporine or tacrolimus is the optimal CNI; this debate has been comprehensively reviewed previously [80, 81] .
Pharmacokinetics

Absorption, Distribution, Metabolism and Excretion
To choose the appropriate target trough concentration for an individual patient, the pharmacodynamic association of CNI concentrations with clinical outcomes must be interpreted cautiously with respect to the alloHCT characteristics (detailed in Sect. 2), the methods and timing of pharmacokinetic sampling [82] and the analytical method used for quantification of the CNI concentrations. Artificially high cyclosporine concentrations may be due to desorption of cyclosporine from the material of central venous catheters [83] . Close attention should be paid to the analytical method used to quantify cyclosporine. The monoclonal and polyclonal immunoassay methods have cross-reactivity with cyclosporine metabolites and will provide different results than the preferred high-performance liquid chromatography (HPLC) method [84] . More recent immunoassays, such as antibody-conjugated magnetic immunoassay (ACMIA), have no significant intermethod bias compared with liquid chromatography with tandem mass spectrometry (LC-MS/MS) of whole-blood concentrations of cyclosporine or tacrolimus in paediatric transplant patients [85] .
The monoclonal and polyclonal antibody assays crossreact with and measure varying amounts of metabolites in addition to the parent compound [84] . The immunoassay methods can overestimate cyclosporine and tacrolimus drug concentrations, because of cross-reactivity with other drugs and/or chemical moieties on biomolecules [86] [87] [88] . The alternative assay, (LC-MS/MS) is completely specific for the parent compound.
There are limited data to suggest that there is a correlation between CNI concentrations and clinical outcomes. The results from these studies suggest that there may be a complex relationship between dose, blood concentrations and the occurrence of GVHD. Interpretation of the pharmacodynamic studies is also complicated by small heterogeneous samples and insufficient details regarding when the trough samples were drawn relative to the administration time [89] . Thus, it is not surprising that contradictory results have been found.
Both cyclosporine and tacrolimus share the same pathways for absorption, metabolism, distribution and excretion. Both are highly lipophilic, which contributes to their highly variable absorption and extensive metabolism [79] . Oral bioavailability (F) of both drugs is generally poor, with mean values around 25 %, but wide variation in oral bioavailability is seen between individuals using these two drugs [90] . Both cyclosporine and tacrolimus bind extensively to erythrocytes, and only unbound drug is capable of entering lymphocytes and exerting its main immunosuppressive effects [90] . The oral bioavailability and the systemic clearance of both drugs are mainly influenced by CYP 3A4 and 3A5 and the efflux pump Pgp also referred to as multidrug resistance 1 (MDR1) or adenosine triphosphate (ATP)-binding cassette (ABC) sub-family B member 1 (ABCB1). Both CYP3A4 and 3A5, along with Pgp are expressed in the gastrointestinal tract (affecting oral bioavailability) and in the liver (affecting both oral bioavailability and systemic clearance) [79, 91, 92] . After either intravenous or oral administration, less than 1 % [93] of the administered parent drug is excreted unchanged in either the urine or faeces, with the vast majority of metabolites ([95 %) appearing in the faeces [79] . This is mediated by active excretion of these metabolites into the bile or directly into the gut lumen [79] . For cyclosporine, *25 metabolites are formed; the major metabolites found in blood are AM1, AM9 and AM4N [90] . The immunosuppressive activity of these metabolites varies, but all metabolites studied thus far have reduced activity compared with cyclosporine [90] . AM1 has the highest immunosuppressive activity, with its reported activity varying from 20 % to as high as 80 % as active as cyclosporine [90] . Up to 15 metabolites of tacrolimus may be formed. The most prevalent metabolite, 13-O-demethyl-tacrolimus, is approximately one tenth as active as tacrolimus [90] . A minor metabolite, 31-O-demethyltacrolimus, has immunosuppressive activity comparable with that of tacrolimus [90] . The remaining metabolites have weak pharmacological activity [90] .
After myeloablative conditioning regimens, the CNIs usually are administered intravenously until gastrointestinal toxicity (e.g. chemotherapy-induced emesis, diarrhoea) from the conditioning regimen has resolved [34] . Gastrointestinal effects of the conditioning regimen and GVHD affect the oral absorption of microemulsion cyclosporine and may result in inconsistent blood concentrations [94] . Older pharmacokinetic data came from a study of an earlier formulation of cyclosporine, Sandimmune Ò , which has an intravenous-to-oral ratio of 1:4 [84] . With the newer microemulsion formulations, a ratio of 1:2 [95] or 1:3 is used when converting from intravenous to oral dosing. Tacrolimus has a ratio of 1:4 when converting from intravenous to oral dosing [84] . Different conversion ratios for intravenous to oral regimens may be used when patients are receiving concomitant medications that affect CYP3A4 or Pgp such as itraconazole.
The maximum plasma concentration (C max ) and area under the concentration-time curve (AUC) values of both cyclosporine and tacrolimus are higher in the morning than in the afternoon [93] . Seasonal variation is also of concern, as it has recently been reported that duodenal CYP3A4 messenger RNA (mRNA) is significantly higher when the UV-B index is highest compared with the months with the lowest UV-B index [96] . The cyclosporine population clearance in alloHCT patients ranges from 8.4 L/h [97] 
Pharmacogenomics
Genetic polymorphisms of CYP3A4, CYP3A5 and Pgp may impact the pharmacokinetics of CNIs [103] . Although there is a paucity of such data from alloHCT recipients, recent data indicate that single nucleotide polymorphisms (SNPs) of CYP3A5 are associated with the pharmacokinetics of cyclosporine [104, 105] or tacrolimus [106] and that ABCB1 polymorphisms are associated with cyclosporine pharmacokinetics [105] .
Drug-Drug Interactions
As noted in Sect. 4 , much of what is currently known about potential DDIs in alloHCT is extrapolated from studies conducted in the setting of solid organ transplantation [73] [74] [75] . Examples of potential DDIs in alloHCT are those resulting from concomitant calcium channel blockers, imatinib, antibiotics or antifungals, which are needed because of the immunosuppression of alloHCT recipients [70, 107, 108] . Because of routine TCI of trough or predose concentrations of the CNI, these results can be used to identify a DDI and appropriately change the dose of the CNI. For example, the DDI between azole antifungals and CNIs has long been recognized [109, 110] and can be managed through TCI [70] . The azoles have variable CYP3A4 inhibition and potentially also affect CYP2C9, CYP2C19 and Pgp [70] . The risk of deleterious DDIs led to a change in the primary end point of prophylactic antifungal trials from invasive fungal infections to failure-free survival [78] . Failure-free survival provides a net assessment of the efficacy of the antifungal in preventing an invasive fungal infection and any negative effect of mortality from adverse events, some of which arise from deleterious DDIs [78] . Although these azole-immunosuppression DDIs are well known, their management can be variable and could benefit from improved pharmacokinetic/ pharmacodynamic modelling. Notably, recipients of nonmyeloablative alloHCT have an increased burden of comorbidities, potentially increasing the number of concomitant medications and potential DDIs affecting the pharmacokinetics of the CNI.
Special Populations
6.1.4.1 Renal or Hepatic Impairment The impact of renal or hepatic impairment upon the pharmacokinetics of CNIs has been minimally characterized. A previous population study in 122 adult alloHCT patients found that bilirubin, serum creatinine, GVHD and sinusoidal obstruction syndrome significantly influenced tacrolimus clearance [99, 101] . In 22 paediatric alloHCT recipients, tacrolimus clearance decreased with increasing serum creatinine [101] . Notably, recent data have suggested that diabetes, a common cause of renal dysfunction, alters tacrolimus metabolism, although further studies are needed [111] .
Paediatrics
With intravenous cyclosporine, age was a covariate for clearance in 27 alloHCT recipients aged 0.9-20 years [112] . Children have more rapid intravenous tacrolimus clearance than adults [100, 113] , and careful TCI in the first 2 weeks after allograft infusion has been recommended [100] . In 22 paediatric alloHCT patients, Wallin et al. reported the following intravenous tacrolimus parameters: typical clearance was 106 mL/h 9 kg 0.75 , the typical distribution volume was 3.71 L/kg and typical oral bioavailability was 15.7 % [101] . Tacrolimus clearance decreased with increasing serum creatinine, and oral bioavailability decreased with postgraft infusion day [101] .
6.1.4.3 Obesity Obesity has no significant effect upon the volume of distribution or clearance of cyclosporine [114] . The American Society for Blood and Marrow Transplantation (ASBMT) guidelines do not address cyclosporine or tacrolimus dosing in obese patients [115] . The current dosing and TCI methods for obese children appear sufficient, since no difference in survival was observed in 3687 paediatric alloHCT recipients of differing body mass indices (BMIs) with various haematological malignancies [116] . Unfortunately, the dosing methods were not specified in this Center for International Blood and Marrow Transplant Research (CIBMTR) dataset. However, the Best Pharmaceuticals for Children ActPediatric Trials Network Administrative Core Committee's systemic review identified one study of cyclosporine pharmacokinetics in obese children [117] . In adolescent renal transplant recipients, cyclosporine doses after correction for body weight, bone mass index or body surface area (BSA) were significantly lower in patients who were obese (BMI [95th percentile) or overweight (BMI [85th percentile) compared with controls (BMI \95th percentile or \85th percentile, respectively) [118] . Despite this difference in doses, the obese and overweight adolescents achieved similar trough and 2 h post-dose cyclosporine concentrations compared with the controls [118] .
Pharmacodynamic Measurements
Various biomarkers have been evaluated to measure the pharmacodynamic response to CNIs. While methods to assess calcineurin activity have been available for over 25 years [119] , the two studies in alloHCT recipients have yielded conflicting findings regarding the association between calcineurin activity and acute GVHD [120, 121] . There are numerous limitations to calcineurin activity quantitation. These limitations have been recently overcome, but calcineurin activity has yet to be associated with clinical outcomes in solid organ transplant recipients [122, 123] . Pai et al. characterized calcineurin activities in mononuclear cells isolated from 12 healthy volunteers and 62 alloHCT recipients, 33 of whom were administered cyclosporine and 29 of whom were not [121] . Calcineurin activity was significantly suppressed by cyclosporine administration. Among patients administered cyclosporine, calcineurin activity was lower in those with acute GVHD than in those without acute GVHD. Calcineurin activity was comparable among patients with and those without chronic GVHD. The lower calcineurin activity of patients with acute GVHD suggests that cyclosporine-resistant GVHD did not result from inadequate suppression of calcineurin activity. Likewise, if calcineurin inhibition is the only physiological target of cyclosporine, increased cyclosporine doses or use of an alternative CNI would not ameliorate GVHD. Subsequently, Sanquer et al. evaluated the association of calcineurin activity during the first 2 months after alloHCT graft infusion with acute GVHD in 31 alloHCT recipients treated with cyclosporine prophylaxis (2 mg/kg/day) and methotrexate (on days ?1, ?3 and ?6) [120] . Calcineurin activity was measured before alloHCT and then once weekly for at least 2 months. In contrast to the prior findings, calcineurin activity was significantly increased in the 18 patients with GVHD compared with the 13 who did not develop GVHD. Although this group concluded that calcineurin activity was a promising test to predict acute GVHD, no further studies have been reported.
More recently, methods have been developed to evaluate the inhibitory effect of the CNIs upon interleukin 2 (IL-2) mRNA expression both in vitro and ex vivo. These methods have been developed using samples obtained from healthy volunteers [124] and have only recently been applied to renal transplant patients [125] . Data regarding IL-2 mRNA expression after CNI administration in alloHCT recipients were not found. Research is also ongoing to quantify the relationship between cyclosporine trough whole-blood concentrations and neutrophil response in children with severe aplastic anaemia, with neutrophil response being a biomarker of response [126] .
Target Concentration Intervention
Recent Pharmacodynamic Studies
As noted earlier (see Sect. 2.3), the addition of cyclosporine to GVHD prophylaxis-known as the Seattle regimen (i.e. cyclosporine/methotrexate regimen [34] )-substantively improved outcomes after alloHCT. TCI was rapidly accepted to dose cyclosporine on the basis of trough concentrations in whole blood and was subsequently implemented for tacrolimus dosing; TCI of CNIs is now widely accepted clinically [127] [128] [129] . The principal adverse effects associated with CNIs are neurotoxicity, nephrotoxicity, hypertension, hyperglycaemia, magnesium wasting, gastrointestinal disturbances, infections and malignancy [90] . The dose of cyclosporine or tacrolimus is adjusted on the basis of trough drug concentrations and the serum creatinine concentration. Furthermore, CNIs have substantial DDI liability, which is often mitigated by careful trough monitoring (see Sect. 6.1.3).
To choose the appropriate target trough concentration for an individual patient, the pharmacodynamic association of CNI concentrations with clinical outcomes must be interpreted cautiously with respect to the alloHCT characteristics (detailed in Sect. 2) and with respect to the pharmacokinetic sampling techniques [82, 83] and the quantification method. The historical pharmacodynamic data on cyclosporine with outcomes have been reviewed previously [114] ; the results of pharmacodynamic studies reported within the past decade are summarized in Table 3 [130]. The Seattle group reported the largest pharmacodynamic study in alloHCT, analysing data from more than 1000 patients with haematological malignancies who had alloHCT from HLA-matched related or unrelated donors over a 10-year time period [130] . After myeloablative conditioning, higher CNI concentrations were not associated with lower risks of acute or chronic GVHD (Fig. 2) . In contrast, in a study of over 400 patients undergoing nonmyeloablative alloHCT, higher cyclosporine concentrations were associated with decreased risks of grade II-IV and grade III-IV acute GVHD, NRM and overall mortality. Cyclosporine concentrations were not associated with risks of chronic GVHD and recurrent malignancy after nonmyeloablative alloHCT. Among patients given tacrolimus after nonmyeloablative alloHCT, a similar trend of CNI-associated GVHD protection was observed. Importantly, higher cyclosporine concentrations were not associated with an increased risk of renal dysfunction. Thus, higher cyclosporine concentrations relatively early (i.e. at week 2 after graft infusion) after nonmyeloablative alloHCT appear to confer protection against acute GVHD, which translates into reduced risks of non-relapse and overall mortality. Specifically, a cyclosporine trough concentration above 345 ng/mL (LC-MS/MS) provided incremental protection against grade II-IV and grade III-IV acute GVHD in patients receiving cyclosporine (intravenously or orally) every 12 h. There were, however, some limitations of this retrospective analysis, which were noted by the authors and in an accompanying editorial [131] . A large prospective trial showed only a trend towards an association between low cyclosporine concentrations and increased GVHD risk, whereas no association was found between tacrolimus concentrations and GVHD risk [132] . Furthermore the significance of lower cyclosporine concentrations was predominantly based on the worse outcomes in the lower quartile of the population [130] . Notably, in patients given tacrolimus, higher week 2 mean levels were correlated with the risk of grade III-IV, but not grade II-IV, acute GVHD. Also, it is not clear why a pharmacodynamic association was found only after nonmyeloablative conditioning; this was perhaps related to the use of MMF instead of methotrexate. The results of studies • Not evaluated Acute GVHD:
• Higher weighted average CSA trough concentrations early post-transplantation contributed to lower risk of acute GVHD
• In the multivariable models, after adjustment for donor type and conditioning regimen, it was observed that every 50 ng/mL increase in the weighted average CSA trough concentration resulted in 33 % reduction in risk of grade II-IV acute GVHD Chronic GVHD:
• CSA not associated with chronic GVHD risk NRM and overall mortality:
• Higher weighted average CSA trough concentration early post-transplantation contributed to lower NRM and lower overall mortality
• Higher weighted average CSA concentration also resulted in 33 % reduction in risk of NRM and a 23 % reduction in risk of overall mortality • In MA and NMA alloHCT, higher CNI concentrations were not associated with apparent renal toxicity Acute GVHD:
• After MA alloHCT, higher CSA or TAC trough concentrations were not associated with lower risk of acute GVHD
• After NMA alloHCT, high CSA trough concentrations were associated with decreased risk of grade II-IV and grade III-IV acute GVHD (HR per 100 ng/mL change in CSA concentrations: 0. • Similar trends seen in NMA patients receiving TAC Chronic GVHD:
• After nonmyeloablative alloHCT, CSA trough concentrations were not associated with risks of chronic GVHD or recurrent malignancy NRM and overall mortality:
• After nonmyeloablative alloHCT, higher CSA trough concentrations were associated with decreased risks of • Acute GVHD was scored as 0 (none) or 1 (any acute GVHD), not graded according to severity
Renal toxicity:
• Not evaluated Acute GVHD:
• At steady state, the average concentration in the effect compartment was significantly related to the probability of acute GVHD occurrence (p \
0.05)
Chronic GVHD:
• Not evaluated NRM and overall mortality:
• Not evaluated • Among 145 children who met initial inclusion criteria, 91 had sufficient evaluable data to be included • Estimated CSA AUC using a popPK model incorporating body weight and time post-alloHCT as covariates to estimate clearance and then AUC
• Acute GVHD was graded according to standard criteria Renal toxicity:
• No association between CSA AUC and incidence of acute GVHD
• Lower CSA trough concentrations during early postalloHCT period were associated with higher risk of acute GVHD. Hazard decreases for every additional 10 ng/mL; HR: 0.79 [95 % CI 0.56-0.96], p = 0.02
• CSA trough concentrations were not associated with NRM or overall survival (p [
• CSA AUC (AUC [3000 lg 9 h/L vs. AUC \3000 lg 9 h/L) was not associated with NRM (p = 0.28) but was associated with overall survival (p = 0.03) in overall population Other:
• CSA trough concentrations were not associated with relapse in the overall patient population (N = 91), in patients with ALL (N = 35) or in patients with AML (N = 31)
• CSA AUC was associated with relapse rate in the overall population (p = 0.03) and in AML patients (p = 0.04) but not in patients with ALL (p = 0.89) Table 3 continued Renal toxicity:
• Univariate analysis revealed that MUDs and those with lowest CSA trough concentrations in weeks 1 and 2 had significantly higher risk of grade III-IV acute GVHD
• Multivariate logistic regression analysis revealed that higher CSA trough concentrations in week 1 were the strongest parameter significantly associated with a reduced risk of severe grade III-IV acute GVHD (RR: 0. • Not evaluated NRM and overall mortality:
• Not evaluated • Proportion of time when each patient had a wholeblood CSA trough concentration within or above initial target calculated by week from days 0 to ?28, within week leading up to engraftment and within week leading up to acute GHVD onset Renal toxicity:
• • Multivariable analysis demonstrated an inverse relationship between median CSA concentrations during the week before engraftment and development of severe acute GVHD Chronic GVHD:
• Not evaluated
Only studies evaluating the association of whole-blood concentrations with clinical outcomes in alloHCT recipients over the past 10 years are included. Studies from within the past 10 years that focused only upon pharmacokinetics [112] In the abstract by Malard et al. [179] , these p values and relative risks are given for grade II-IV acute GVHD, while in the body of the manuscript, the same p values and relative risks are given for grade III-IV acute GVHD in smaller alloHCT populations are also summarized in Table 3 . CNI doses are adjusted for the occurrence of GVHD and increased serum creatinine [133] . The role of TCI to ameliorate nephrotoxicity, however, is unclear. Elevated cyclosporine trough concentrations (via immunoassay or HPLC assay) are associated with a higher incidence of nephrotoxicity [134, 135] , but contradictory results have been reported [130, 136] . Cyclosporine-induced nephrotoxicity can occur even at low or normal concentrations of cyclosporine and may be a consequence of other drug-or disease-related factors known to influence the development of nephrotoxicity (e.g. genetic risk factors, concurrent use of other nephrotoxic agents, sepsis) [136, 137] . Furthermore, pharmacogenomic risk factors for acute kidney injury have also been elusive. A retrospective trial of 121 patients found no pharmacogenomic association between CYP3A5*1[*3 and ABCB1 SNPs (1199G[A, 1236C[T, 2677G[T/A and 3435C[T) and acute kidney injury, defined as doubling of baseline serum creatinine during the first 100 days after alloHCT, or chronic kidney disease, defined as at least one glomerular filtration rate (GFR) less than 60 mL/min/m 2 between 6 and 18 months after alloHCT [138] .
Current Target Concentration Intervention
The precise timing of the initiation, dose and TCI methods often differ between transplant centres, so only general trends are reviewed here. The CNIs should be initiated before or immediately after donor cell infusion (i.e. days -3 to 0) when used for postgraft immunosuppression [130, 139] . This schedule is recommended because of the CNIs' known mechanism of action: the phosphatase activity of calcineurin is inhibited, which subsequently leads to lower formation and secretion of several cytokines by T lymphocytes, eventually resulting in a diminished inflammatory alloreactive response [79, 81] .
TCI of cyclosporine and tacrolimus is performed by adjusting drug dosages with the goals of improved effectiveness and decreased toxicity. Evidence of an advantage for dosing tacrolimus or cyclosporine with versus without TCI has not been formally established in a randomized control trial. Given the narrow therapeutic indices of these agents, however, and their large interindividual pharmacokinetic variability, it is widely accepted that TCI is beneficial [90, 140] .
There is no consensus in North America regarding the optimal target whole-blood cyclosporine trough [130] concentrations, and targets vary widely between institutions [82, 141] . The European Group for Blood and Marrow Transplantation and the European LeukemiaNet (EBMT-ELN) Working Group recommendations for a standardized practice in the prophylaxis of GVHD recommended a cyclosporine trough of 200-300 ng/mL (quantification method not specified) during the first 3-4 weeks and then 100-200 ng/mL until day ?90 after alloHCT if there is no GVHD or toxicity [44] . Target tacrolimus concentrations for TCI after myeloablative conditioning are generally whole-blood trough concentrations of 5-15 ng/mL after LC-MS/MS analysis. Tacrolimus concentrations [20 ng/mL are associated with an increased risk of toxicity, particularly nephrotoxicity [132, 142] . In nonmyeloablative alloHCT patients, CNI concentrations over the first 28 days are generally targeted higher than in myeloablative patients. Because no standard guidelines for TCI exist, however, most centres adopt their own approach.
Newer Methods for Target Concentration Intervention
Numerous studies have evaluated cyclosporine TCI on the basis of the AUC rather than the more commonly used trough concentrations in alloHCT [112, [143] [144] [145] [146] [147] [148] [149] [150] [151] . Pharmacokinetic sampling to determine the AUC has potential drawbacks, as it often entails a high level of patient inconvenience, potentially an inpatient admission, a high workload to obtain the samples, a large total blood sample volume and high assay costs [82] . Therefore, the development of limited sampling schedules (LSSs) is desirable. Using LSSs can help to facilitate the TCI of cyclosporine by reducing the need for intensive, invasive sample collection, improving convenience and lowering costs. Numerous studies have been published describing LSSs to estimate total cyclosporine following intravenous [82, 152] or oral [149, 153, 154] administration. The majority of these studies require measurement of cyclosporine concentrations within the first 4 h following a dose using either multiple linear regression [82, 149, 152, 154] or a maximum a posteriori (MAP) Bayesian procedure [153, 154] to estimate the cyclosporine AUC. For both intravenous and oral cyclosporine, an LSS of 3-5 samples can estimate the cyclosporine AUC from 0 to 12 h (AUC 12 ) with satisfactory accuracy (low bias and precision) relative to intensive pharmacokinetic sampling. A MAP Bayesian personalization approach has been reported for cyclosporine trough concentration TCI in children [155] . Van Rossum et al. has recently stated that popPK, using an LSS for AUC estimates and a Bayesian estimator, is the preferred TCI strategy after solid organ transplantation [156] . Furthermore, the construction of physiologically based pharmacokinetic models has allowed for simulations to evaluate the optimal administration schedule of cyclosporine. Gerard et al. recently showed that intermittent infusions (i.e. a 2 h infusion administered every 12 h) were associated with higher simulated cyclosporine concentrations in the GVHD target organs but lower simulated cyclosporine concentrations in the kidney, suggesting that intermittent infusions would be superior [157] .
Although various LSSs have been developed for tacrolimus in solid organ transplant recipients [158] , none could be found for alloHCT recipients.
Methotrexate
Methotrexate is a structural analogue of folic acid, which is a required cofactor for the synthesis of purines and thymidine. The antiproliferative effects of methotrexate are likely related to its effectiveness for postgraft immunosuppression, although the precise mechanism by which methotrexate prevents GVHD is not understood [81] . Donor lymphocytes rapidly proliferate after alloHCT in response to the host antigens. Methotrexate is an inhibitor of dihydrofolate reductase (DHFR), the enzyme responsible for converting folates into their active, reduced tetrahydrofolate forms [159] . The immunosuppressive properties of methotrexate result from the depletion of intracellular tetrahydrofolate pools, leading to depletion of purines and thymidylate, and subsequent inhibition of DNA synthesis in the lymphocytes [159] . A combination of methotrexate and CNI (the Seattle regimen) is the most widely used postgraft immunosuppressive regimen following myeloablative conditioning [34, 36, 39] . The Seattle regimen consists of a CNI administered daily and short-course methotrexate administered on days ?1, ?3, ?6 and ?11 post-transplantation. This schedule is based on dog studies, which indicated that more frequent methotrexate dosing led to severe gastrointestinal toxicity [160] . Several modifications to methotrexate dosing [34, 36, 161, 162] and leucovorin rescue use (and leucovorin dosing) have been described [44] . While the Seattle regimen is the most widely published [34] , there is no consensus in the USA [66] , and only a recent consensus in Europe [44] , with regard to the preferred regimen.
Pharmacokinetics
Absorption, Distribution, Metabolism and Excretion
Methotrexate is administered only intravenously to alloHCT recipients, and no studies evaluating the absorption of methotrexate in this patient population were found.
In pharmacokinetic data outside alloHCT, the volume of distribution of methotrexate is 9.03 ± 4.70 L/m 2 (mean ± standard deviation) and the elimination rate constant is 0.70 ± 0.22 1/h (mean ± standard deviation) [163] . Methotrexate binds primarily to albumin and is approximately 50 % bound [164] . The presence of ascites or effusions can provide a clinically important reservoir for residual methotrexate, leading to a sustained release of low, but cytotoxic, methotrexate concentrations into the plasma. The intracellular transport of methotrexate involves an active (carrier-mediated) process at low extracellular concentrations; above low concentrations, transport is primarily by passive diffusion. Less than 10 % of an intravenous methotrexate dose is eliminated by the gastrointestinal tract, and intestinal bacteria can metabolize methotrexate [164] . Urinary excretion of the parent drug is the major route of methotrexate elimination. Methotrexate is filtered and reabsorbed, and undergoes storable, active tubular secretion [164] . The typical time course of plasma methotrexate pharmacokinetics is biexponential, with a mean initial half-life of approximately 1.5-3.5 h and a typical terminal half-life of 8-15 h [164] . Altered pharmacokinetics are seen in children before adolescence and in patients with renal dysfunction [164] .
As part of a DDI study, Wingard et al. evaluated methotrexate pharmacokinetics in alloHCT recipients of HLA-identical sibling bone marrow grafts [165] . Methotrexate was administered at a dose of 15 mg/m 2 on day ?1, followed by 10 mg/m 2 on days ?3, ?6 and ?11 after graft infusion. Serum methotrexate samples were drawn before and at 8, 16, 24 and 36 h after the doses on days ?1 and ?6. These serum samples were analysed at a central laboratory using fluorescence polarization immunoassay (TxD; Abbott, Chicago, IL, USA) and noncompartmental modelling [165] . Eighty patients consented to this study, half of whom received cyclosporine plus methotrexate (cyclosporine/methotrexate) and half of whom received tacrolimus plus methotrexate (tacrolimus/ methotrexate). Of these patients, 16 (40 %) of the cyclosporine/methotrexate patients and 26 (65 %) of the tacrolimus/methotrexate patients were not included in the day ?1 and day ?6 analyses, either because they did not receive full-dose methotrexate or because of incomplete sample collection. There were no significant differences in the methotrexate AUC or methotrexate serum concentrations between the cyclosporine and tacrolimus cohorts at any of the sampled time points. Renal function was similar in the cyclosporine and tacrolimus cohorts. On day ?1, the median (range) values of the serum methotrexate AUC (lmol/h/L) were 1.60 (0.00-3.12) for the cyclosporine cohort and 1.84 (0. 16-4.46) for the tacrolimus cohort. On day ?6, the median (range) values of the serum methotrexate AUC (reported as lmol/h/L) were 1.20 (0.04-1.32) for the cyclosporine cohort and 1.54 (0.08-3.14) for the tacrolimus cohort. The higher serum methotrexate AUC on day ?1 compared with day ?6 is expected, since a higher methotrexate dose is administered on day ?1 (15 mg/m 2 ) than on day ?6 (10 mg/m 2 ). Notably, only three of the 42 patients (5 %) had serum methotrexate concentrations at 24 h greater than or equal to 0.05 lmol/L, which is generally the recommended threshold for administering leucovorin rescue [164] . The methotrexate clearance did not differ between patients with or without advanced cancer. A pharmacodynamic analysis was not reported.
Kim et al. evaluated the pharmacokinetics/pharmacogenomics of methotrexate in alloHCT recipients [166] . Twenty adult alloHCT recipients received cyclosporine with methotrexate (15 mg/m 2 on day ?1 followed by 10 mg/m 2 on days ?3, ?6 and ?11 postgraft infusion). The participants had pharmacokinetic sampling following the administration of methotrexate on days ?1, ?3 and ?11. The plasma methotrexate concentrations were determined by LC-MS/MS, and the 94 available concentrationtime points available were subsequently used to build a popPK model. A two-compartment structural model with an exponential error model was used. The pharmacokinetic parameters of methotrexate clearance and the volume of distribution in the central compartment were evaluated with the following covariates: sex, age, BSA, donor type, serum creatinine, creatinine clearance (CL CR ), albumin, aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin, urine pH, concomitant drug treatment, and genetic polymorphisms of ABCB1, ABC sub-family C member 1 (ABCC1), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthetase (TYMS). Methotrexate clearance was significantly affected by the GFR (in mL/min, as estimated by the Cockcroft-Gault equation), concomitant penicillin administration and the ABCB1 3435 genotype. For every 10 mL/ min increase in GFR, the methotrexate clearance increased. Concurrent penicillin administration led to a decrease in methotrexate clearance. The covariates' relationship to clearance (L/h) is given in Eq. 1: 
where PEN equals 1 in patients given penicillin and 0 otherwise, and where HOMZ equals 1 in patients homozygous for the ABCB1 3435 TT genotype and 0 otherwise. Individuals homozygous for a single genetic variant of the ABCB1 transporter (ABCB1 3435 TT) had a *21 % decrease in methotrexate clearance compared with wildtype individuals or carriers of a single mutant allele (ABCB1 3535 CC or CT). The population clearance and volume of distribution in the central compartment were 7.08 L/h and 19.4 L, respectively. The between-subject variability (BSV) of clearance and the volume of distribution were estimated to be 21.6 and 73.3 %, respectively. The proportional term estimate for residual unexplained variability (RUV) was 37.8 %. Similar to the CNIs (see Sect. 6.1.1), HPLC is more specific for methotrexate concentrations than enzyme immunoassay or radioimmunoassay [167] .
Pharmacogenomics
As noted in Sect. 7.1.1, methotrexate clearance was impacted by the ABCB1 3435 TT genotype but not by the ABCC1, ATIC, GGH, MTHFR or TYMS genotypes in a study of 20 adult alloHCT recipients [166] . MTHFR and TYMS play essential roles in intracellular folate metabolism. The association of acute GVHD [168] with genetic variations in recipient and donor MTHFR (C677T and A1298C) and TYMS (enhancer-region 28-base pair repeat, TSER and 1494del6) genotypes has been evaluated in 304 adult alloHCT recipients. The risk of acute GVHD was associated with variant MTHFR alleles in the recipient, but no association was observed for donor MTHFR genotypes or for recipient or donor TYMS genotypes [168] . In a subset of this population with oral mucositis data (N = 172), the recipient MTHFR genotypes were associated with the risk of oral mucositis [169] .
Drug-Drug Interactions
There is no apparent difference in methotrexate disposition in patients receiving CNIs, as the methotrexate AUCs (time interval of AUC not specified) after days ?1 and ?6 are similar in patients receiving cyclosporine and those receiving tacrolimus [165] . As discussed in Sect. 7.1.1, Kim et al. demonstrated an interaction between concomitant penicillin and methotrexate in 20 alloHCT recipients [166] . Of these 20 patients, six received piperacillin and tazobactam, and one received ampicillin and sulbactam; the remainder did not receive a penicillin derivative. This DDI is consistent with pharmacokinetic literature from other patient populations [170] [171] [172] . Trimethoprim-sulfamethoxazole (TMP-SMX), often administered to alloHCT recipients as Pneumocystis jiroveci pneumonia prophylaxis, is avoided on days of methotrexate administration because of the ability of sulfonamides to displace methotrexate from plasma binding sites and decrease renal methotrexate clearance, resulting in higher methotrexate concentrations. Because TMP-SMX can delay engraftment, it is usually not administered before engraftment occurs [76] .
Special Populations
7.1.4.1 Renal or Hepatic Impairment, Paediatrics, Obesity Methotrexate is used as postgraft immunosuppression after myeloablative conditioning, which is administered to patients with no or minimal comorbidities. Therefore, it is not surprising that there are, to our knowledge, no publications regarding the pharmacokinetics of methotrexate in alloHCT recipients who have renal or liver impairment. Of note, CNI-induced nephrotoxicity may impair methotrexate clearance and necessitate a dose adjustment. There are also no reports of methotrexate pharmacokinetics in paediatric or obese alloHCT recipients. Notably, recent ASBMT guidelines did not address methotrexate dosing in obese patients [115] .
Current Target Concentration Intervention
Although two pharmacokinetic studies of methotrexate were available, no published pharmacodynamic studies or TCI studies could be found for methotrexate in the setting of alloHCT. This contrasts with the wealth of pharmacokinetic/pharmacodynamic studies of high-dose methotrexate used to treat childhood lymphoblastic leukaemia [163] . With high-dose methotrexate, methotrexate concentration-time data are used to guide leucovorin rescue with the intent of lowering toxicity. The underlying reasons for a lack of pharmacokinetic/pharmacodynamic data are not known, but contributing factors may be delayed turn-around time for obtaining pharmacokinetic results and the narrow time window of methotrexate following alloHCT versus multiple cycles of methotrexate in other patient populations. Even in alloHCT, however, methotrexate toxicity-mainly in the form of hepatic, renal and mucosal toxicities-often mandates dose reductions, with only two thirds of patients receiving the full methotrexate dose [39, 173] . It has been suggested that the methotrexate dose be held in alloHCT recipients with a bilirubin [5 mg/dL or creatinine [2 mg/dL [81] . A higher prevalence of acute GVHD between days ?7 and ?11 has been observed with methotrexate dose reductions [81] .
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